|

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

RECRUITINGSponsored by Istanbul Saglik Bilimleri University
Actively Recruiting
SponsorIstanbul Saglik Bilimleri University
Started2026-05-30
Est. completion2026-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 years or older
* Diagnosis of obesity (BMI \>30 kg/m²)
* Currently using a GLP-1 RA
* No hearing, speech or cognitive impairment
* Not receiving treatment for major depressive disorder and not using antidepressants
* Verbal consent to participate

Exclusion Criteria:

* Diagnosis of diabetes
* History of chronic kidney failure, chronic liver disease, decompensated heart failure or malignancy
* Pregnancy or breastfeeding
* Walking impairment
* Not meeting inclusion criteria or unwilling to participate

Conditions3

DiabetesObesitySarcopenia

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.